Abstract
Oroxylin A (OA), a well-known constituent of the root of Scutellariae plants, has been used in ethnomedicine already for centuries in treating various neoplastic disorders. However, only recent molecular studies have revealed the different mechanisms behind its action, demonstrating antiproliferative, anti-inflammatory, and proapoptotic effects, restricting also the spread of cancer cells to distant organs. A variety of cellular targets and modulated signal transduction pathways regulated by OA have been determined in diverse cells derived from different malignant tissues. In this review article, these anticancer activities are thoroughly described, representing OA as a potential lead structure for the design of novel more potent anticancer medicines. In addition, co-effects of this natural compound with conventional anticancer agents are analyzed and the advantages provided by nanotechnological methods for more efficient application of OA are discussed. In this way, OA might represent an excellent example of using ethnopharmacological knowledge for designing modern medicines.
This is a preview of subscription content, log in via an institution to check access.
Similar content being viewed by others
Data availability
All the data are available with the corresponding author. The data will be provided on request.
Change history
15 April 2024
A Correction to this paper has been published: https://doi.org/10.1007/s00210-024-03083-x
References
Aggarwal V, Kashyap D, Sak K et al (2019) Molecular mechanisms of action of tocotrienols in cancer: recent trends and advancements. Int J Mol Sci 20:. https://doi.org/10.3390/ijms20030656
Aggarwal V, Tuli HS, Kaur J et al (2020) Garcinol exhibits anti-neoplastic effects by targeting diverse oncogenic factors in tumor cells. Biomedicines 8:103. https://doi.org/10.3390/BIOMEDICINES8050103
Aguilar-Sáenz A, Treviño-Saldaña N, Oropeza-Almazán Y, García-Rivas G (2018) Oroxylin A prevents cardiac hypertrophy and dysfunction as a modulator of mitochondrial protein acetylation. FASEB J 32:675.14-675.14. https://doi.org/10.1096/fasebj.2018.32.1_supplement.675.14
An D, Song Z, Yi Y et al (2019) Oroxylin A, a methylated metabolite of baicalein, exhibits a stronger inhibitory effect than baicalein on the CYP1B1-mediated carcinogenic estradiol metabolite formation. Phytother Res 33:1033–1043. https://doi.org/10.1002/ptr.6297
Anand U, Jacobo-Herrera N, Altemimi A, Lakhssassi N (2019) A comprehensive review on medicinal plants as antimicrobial therapeutics: potential avenues of biocompatible drug discovery. Metabolites 9:258. https://doi.org/10.3390/METABO9110258
Anand U, Nandy S, Mundhra A et al (2020) A review on antimicrobial botanicals, phytochemicals and natural resistance modifying agents from Apocynaceae family: possible therapeutic approaches against multidrug resistance in pathogenic microorganisms. Drug Resist Updates 51:100695. https://doi.org/10.1016/j.drup.2020.100695
Anand U, Tudu CK, Nandy S et al (2022) Ethnodermatological use of medicinal plants in India: From ayurvedic formulations to clinical perspectives – a review. J Ethnopharmacol 284:114744. https://doi.org/10.1016/j.jep.2021.114744
Azad MB, Chen Y, Gibson SB (2009) Regulation of autophagy by reactive oxygen species (ROS): implications for cancer progression and treatment. Antioxid Redox Signal 11:777–790. https://doi.org/10.1089/ars.2008.2270
Bian M, He J, Jin H et al (2019) Oroxylin A induces apoptosis of activated hepatic stellate cells through endoplasmic reticulum stress. Apoptosis 24:905–920. https://doi.org/10.1007/s10495-019-01568-2
Bouïs D, Kusumanto Y, Meijer C et al (2006) A review on pro- and anti-angiogenic factors as targets of clinical intervention. Pharmacol Res 53:89–103. https://doi.org/10.1016/J.PHRS.2005.10.006
Cao K, Tait SWG (2018) Apoptosis and cancer: force awakens, phantom menace, or both? In: International Review of Cell and Molecular Biology. Int Rev Cell Mol Biol, pp 135–152
Cao Y, Cao W, Qiu Y et al (2020) Oroxylin A suppresses ACTN1 expression to inactivate cancer-associated fibroblasts and restrain breast cancer metastasis. Pharmacol Res 159:. https://doi.org/10.1016/j.phrs.2020.104981
Cao HJ, Zhou W, Xian X Le et al (2022) A mixture of baicalein, wogonin, and oroxylin-A inhibits EMT in the A549 cell line via the PI3K/AKT-TWIST1-glycolysis pathway. Frontiers in Pharmacology 12:. https://doi.org/10.3389/fphar.2021.821485
Carmeliet P, Jain RK (2011) Molecular mechanisms and clinical applications of angiogenesis. Nature 473:298–307. https://doi.org/10.1038/nature10144
Carrasco-Esteban E, Domínguez-Rullán JA, Barrionuevo-Castillo P et al (2021) Current role of nanoparticles in the treatment of lung cancer. J Clin Transl Res 7:140. https://doi.org/10.18053/jctres.07.202102.005
Cheng Y, Zhao K, Li G et al (2014) Oroxylin A inhibits hypoxia-induced invasion and migration of MCF-7 cells by suppressing the Notch pathway. Anticancer Drugs 25:778–789. https://doi.org/10.1097/CAD.0000000000000103
Chien JY, Lin SF, Chou YY et al (2021) Protective effects of oroxylin a on retinal ganglion cells in experimental model of anterior ischemic optic neuropathy. Antioxidants 10:. https://doi.org/10.3390/antiox10060902
Collins K, Jacks T, Pavletich NP (1997) The cell cycle and cancer. Proc Natl Acad Sci USA 94:2776–2778. https://doi.org/10.1073/pnas.94.7.2776
Cui XB, Qian XC, Huang P et al (2015) Simultaneous determination of ten flavonoids of crude and wine-processed Radix Scutellariae aqueous extracts in rat plasma by UPLC-ESI-MS/MS and its application to a comparative pharmacokinetic study. Biomed Chromatogr 29:1112–1123. https://doi.org/10.1002/bmc.3398
Cui X, Cai H, Li H et al (2016) Simultaneous determination of 10 flavonoids in crude and wine-processed radix scutellariae by UHPLC. J Chromatogr Sci 54:312–317. https://doi.org/10.1093/chromsci/bmv143
Dai Q, Yin Q, Wei L et al (2016) Oroxylin A regulates glucose metabolism in response to hypoxic stress with the involvement of Hypoxia-inducible factor-1 in human hepatoma HepG2 cells. Mol Carcinog 55:1275–1289. https://doi.org/10.1002/mc.22369
Das A, Baidya R, Chakraborty T et al (2021a) Pharmacological basis and new insights of taxifolin: a comprehensive review. Biomed Pharmacother 142:112004. https://doi.org/10.1016/j.biopha.2021.112004
Das T, Anand U, Pandey SK et al (2021b) Therapeutic strategies to overcome taxane resistance in cancer. Drug Resist Updates 55:100754. https://doi.org/10.1016/j.drup.2021.100754
Deka DC, Kumar V, Prasad C et al (2013) Oroxylum indicum- a medicinal plant of North East India: an overview of its nutritional, remedial, and prophylactic properties. J Appl Pharma Sci 3:. https://doi.org/10.7324/JAPS.2013.34.S19
Ding Y, Zhou Y, Li Z et al (2020) Oroxylin A reversed fibronectin-induced glioma insensitivity to temozolomide by suppressing IP3R1/AKT/β-catenin pathway. Life Sci 260:. https://doi.org/10.1016/j.lfs.2020.118411
Egeblad M, Werb Z (2002) New functions for the matrix metalloproteinases in cancer progression. Nat Rev Cancer 2:161–174. https://doi.org/10.1038/NRC745
Ekor M (2014) The growing use of herbal medicines: issues relating to adverse reactions and challenges in monitoring safety. Front Neurol 4 JAN: https://doi.org/10.3389/fphar.2013.00177
Falavarjani KG, Nguyen QD (2013) Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (London, England) 27:787–794. https://doi.org/10.1038/EYE.2013.107
Ferrara N, Kerbel RS (2005) Angiogenesis as a therapeutic target. Nature 438:967–974. https://doi.org/10.1038/NATURE04483
Folkman J (1996) Fighting cancer by attacking its blood supply. Sci Am 275:150–154. https://doi.org/10.1038/SCIENTIFICAMERICAN0996-150
Fong SYK, Li C, Ho YC et al (2017) Brain uptake of bioactive flavones in scutellariae radix and its relationship to anxiolytic effect in mice. Mol Pharm 14:2908–2916. https://doi.org/10.1021/acs.molpharmaceut.7b00029
Furukawa F (2021) Effects of immune checkpoint inhibitors on cancer patients with preexisting autoimmune disease. Trends Immunother 5:5–6. https://doi.org/10.24294/ti.v5.i1.1250
Gaengel K, Betsholtz C (2013) Endocytosis regulates VEGF signalling during angiogenesis. Nat Cell Biol 15:233–235. https://doi.org/10.1038/NCB2705
Gao Y, Lu N, Ling Y et al (2010) Oroxylin A inhibits angiogenesis through blocking vascular endothelial growth factor-induced KDR/Flk-1 phosphorylation. J Cancer Res Clin Oncol 136:667–675. https://doi.org/10.1007/s00432-009-0705-2
Greenberg JI, Shields DJ, Barillas SG et al (2008) A role for VEGF as a negative regulator of pericyte function and vessel maturation. Nature 456:809–814. https://doi.org/10.1038/nature07424
Gupta K, Zhang J (2005) Angiogenesis: a curse or cure? Postgrad Med J 81:236–242. https://doi.org/10.1136/PGMJ.2004.023309
Ha J, Zhao L, Zhao Q et al (2012) Oroxylin A improves the sensitivity of HT-29 human colon cancer cells to 5-FU through modulation of the COX-2 signaling pathway. Biochem Cell Biol 90:521–531. https://doi.org/10.1139/o2012-005
Han X, Kou J, Zheng Y et al (2019) ROS generated by upconversion nanoparticle-mediated photodynamic therapy induces autophagy via PI3K/AKt/ mTOR signaling pathway in M1 peritoneal macrophage. Cell Physiol Biochem 52:1325–1338. https://doi.org/10.33594/000000093
Hemantha HP, Ramanujam R, Majeed M, Nagabhushanam K (2021) An unambiguous and practical synthesis of oroxylin A: a commonly misidentified flavone. Nat Prod Res 35:1413–1420. https://doi.org/10.1080/14786419.2019.1650359
Hirata Y, Tatsu M, Amano C et al (2017) Synergistic antitumor effect of genitinib (Iressa®) with flavonoids from the Scutellaria baicalensis root on the non-small cell lung cells. Open Plant Sci J 10:62–69. https://doi.org/10.2174/1874294701710010062
Hu Y, Yang Y, You QD et al (2006) Oroxylin A induced apoptosis of human hepatocellular carcinoma cell line HepG2 was involved in its antitumor activity. Biochem Biophys Res Commun 351:521–527. https://doi.org/10.1016/j.bbrc.2006.10.064
Hu R, Chen N, Yao J et al (2012) The role of Nrf2 and apoptotic signaling pathways in oroxylin A-mediated responses in HCT-116 colorectal adenocarcinoma cells and xenograft tumors. Anticancer Drugs 23:651–658. https://doi.org/10.1097/CAD.0b013e3283512703
Huang P, Tan S, Zhang YX et al (2014) The effects of wine-processing on ascending and descending: the distribution of flavonoids in rat tissues after oral administration of crude and wine-processed Radix scutellariae. J Ethnopharmacol 155:649–664. https://doi.org/10.1016/j.jep.2014.05.063
Huang XE, Wei D, Yang YN et al (2016) MPTP related mitochondrial pathway in oroxylin A induced-apoptosis in HepG2 cancer cells. Int J Clin Exp Pathol 9:11139–11148
Huang H, Cai H, Zhang L et al (2020) Oroxylin A inhibits carcinogen-induced skin tumorigenesis through inhibition of inflammation by regulating SHCBP1 in mice. Int Immunopharmacol 80:. https://doi.org/10.1016/j.intimp.2019.106123
Hui H, Chen Y, Yang H et al (2014) Oroxylin A has therapeutic potential in acute myelogenous leukemia by dual effects targeting PPARγ and RXRα. Int J Cancer 134:1195–1206. https://doi.org/10.1002/ijc.28435
Huo T-X, Wang X-P, Yu Z et al (2022) Oroxylin A inhibits the migration of hepatocellular carcinoma cells by inducing NAG-1 expression. Acta Pharmacol Sin 43:724–734. https://doi.org/10.1038/s41401-021-00695-4
Jeon SJ, Rhee SY, Seo JE et al (2011) Oroxylin A increases BDNF production by activation of MAPK-CREB pathway in rat primary cortical neuronal culture. Neurosci Res 69:214–222. https://doi.org/10.1016/j.neures.2010.11.008
Jeon SJ, Bak H, Seo J et al (2012) Oroxylin A induces BDNF expression on cortical neurons through Adenosine A2 A receptor stimulation: a possible role in neuroprotection. Biomol Ther 20:27–35. https://doi.org/10.4062/biomolther.2012.20.1.027
Ji Y, Han J, Lee N et al (2020) Neuroprotective effects of baicalein, wogonin, and oroxylin A on amyloid beta-induced toxicity via NF-κB/MAPK pathway modulation. Molecules 25:. https://doi.org/10.3390/molecules25215087
Jiang Y-L, Liu Z-P (2011) Natural products as anti-invasive and anti-metastatic agents. Curr Med Chem 18:808–829. https://doi.org/10.2174/092986711794927711
Jin J, Chen S, Wang D et al (2018) Oroxylin A suppresses influenza A virus replication correlating with neuraminidase inhibition and induction of IFNs. Biomed Pharmacother 97:385–394. https://doi.org/10.1016/j.biopha.2017.10.140
Johansson N, Ahonen M, Kähäri VM (2000) Matrix metalloproteinases in tumor invasion. Cell Mol Life Sci 57:5–15. https://doi.org/10.1007/s000180050495
Karimi A, Majlesi M, Rafieian-Kopaei M (2015) Herbal versus synthetic drugs; beliefs and facts. J Nephropharmacol 4:27–30
Kashyap D, Tuli HS, Garg VK et al (2018) Oncogenic and tumor-suppressive roles of microRNAs with special reference to apoptosis: molecular mechanisms and therapeutic potential. Mol Diagn Ther 22:179–201
Kashyap D, Garg VK, Tuli HS et al (2019) Fisetin and quercetin: promising flavonoids with chemopreventive potential. Biomolecules 9:1–22. https://doi.org/10.3390/biom9050174
Kashyap D, Garg VK, Goel N (2021a) Intrinsic and extrinsic pathways of apoptosis: role in cancer development and prognosis, 1st edn. Elsevier Inc.
Kashyap D, Garg VK, Sandberg EN et al (2021b) Oncogenic and tumor suppressive components of the cell cycle in breast cancer progression and prognosis. Pharmaceutics 13:1–28. https://doi.org/10.3390/pharmaceutics13040569
Kashyap D, Tuli HS, Yerer MB et al (2021c) Natural product-based nanoformulations for cancer therapy: opportunities and challenges. Semin Cancer Biol 69:5–23. https://doi.org/10.1016/j.semcancer.2019.08.014
Kashyap D, Pal D, Sharma R et al (2022) Global increase in breast cancer incidence: risk factors and preventive measures. Biomed Res Int 2022:1–16. https://doi.org/10.1155/2022/9605439
Khare T, Anand U, Dey A et al (2021) Exploring phytochemicals for combating antibiotic resistance in microbial pathogens. Front Pharmacol 12:720726. https://doi.org/10.3389/FPHAR.2021.720726
Kim Y, Jung HJ, Kwon HJ (2012) A natural small molecule voacangine inhibits angiogenesis both in vitro and in vivo. Biochem Biophys Res Commun 417:330–334. https://doi.org/10.1016/j.bbrc.2011.11.109
Kim DH, Lee Y, Lee HE et al (2014) Oroxylin A enhances memory consolidation through the brain-derived neurotrophic factor in mice. Brain Res Bull 108:67–73. https://doi.org/10.1016/j.brainresbull.2014.09.001
Kopustinskiene DM, Jakstas V, Savickas A, Bernatoniene J (2020) Flavonoids as anticancer agents. Nutrients 12:457. https://doi.org/10.3390/nu12020457
Ku WT, Tung JJ, Lee TJF, Lai KC (2019) Long-term exposure to oroxylin a inhibits metastasis by suppressing CCL2 in oral squamous cell carcinoma cells. Cancers 11:. https://doi.org/10.3390/cancers11030353
Kurzyk A (2015) [Angiogenesis - possibilities, problems and perspectives] - PubMed. Postepy Biochem 61:25–34
Kwon BE, Song JH, Song HH et al (2016) Antiviral activity of oroxylin A against coxsackievirus B3 alleviates virus-induced acute pancreatic damage in mice. PLoS ONE 11:e0155784. https://doi.org/10.1371/journal.pone.0155784
Lee JY, Park W (2016) Anti-inflammatory effects of oroxylin A on RAW 264.7 mouse macrophages induced with polyinosinic-polycytidylic acid. Exp Ther Med 12:151–156. https://doi.org/10.3892/etm.2016.3320
Li H-B, Chen F (2004) Preparative isolation and purification of chuanxiongzine from the medicinal plant Ligusticum chuanxiong by high-speed counter-current chromatography. J Chromatogr A 1047:249–253. https://doi.org/10.1016/j.chroma.2004.07.006
Li H-B, Chen F (2005) Isolation and purification of baicalein, wogonin and oroxylin A from the medicinal plant Scutellaria baicalensis by high-speed counter-current chromatography. J Chromatogr A 1074:107–110. https://doi.org/10.1016/j.chroma.2005.03.088
Li HN, Nie FF, Liu W et al (2009) Apoptosis induction of oroxylin A in human cervical cancer HeLa cell line in vitro and in vivo. Toxicology 257:80–85. https://doi.org/10.1016/j.tox.2008.12.011
Li C, Lin G, Zuo Z (2011) Pharmacological effects and pharmacokinetics properties of Radix Scutellariae and its bioactive flavones. Biopharm Drug Dispos 32:427–445. https://doi.org/10.1002/BDD.771
Li C, Zhang L, Zhou L et al (2012) Comparison of intestinal absorption and disposition of structurally similar bioactive flavones in radix scutellariae. AAPS J 14:23–34. https://doi.org/10.1208/s12248-011-9310-9
Li X, Miao H, Zhang Y et al (2015) Bone marrow microenvironment confers imatinib resistance to chronic myelogenous leukemia and oroxylin A reverses the resistance by suppressing Stat3 pathway. Arch Toxicol 89:121–136. https://doi.org/10.1007/s00204-014-1226-6
Li J, Tong D, Liu J et al (2016) Oroxylin A attenuates cigarette smoke-induced lung inflammation by activating Nrf2. Int Immunopharmacol 40:524–529. https://doi.org/10.1016/j.intimp.2016.10.011
Li W, Ding Q, Ding Y et al (2017) Oroxylin A reverses the drug resistance of chronic myelogenous leukemia cells to imatinib through CXCL12/CXCR7 axis in bone marrow microenvironment. Mol Carcinog 56:863–876. https://doi.org/10.1002/mc.22540
Li C, Liu S, Luo G et al (2018a) Comparison of plasma pharmacokinetics of Tanreqing solution between intratracheal aerosolization and intravenous injection in rats. Biomed Chromatogr 32:. https://doi.org/10.1002/bmc.4116
Li H, Lu N, Yu X et al (2018b) Oroxylin A, a natural compound, mitigates the negative effects of TNFα-treated acute myelogenous leukemia cells. Carcinogenesis 39:1292–1303. https://doi.org/10.1093/carcin/bgy004
Lin SF, Chien JY, Kapupara K et al (2017) Oroxylin A promotes retinal ganglion cell survival in a rat optic nerve crush model. PLoS ONE 12:e0178584. https://doi.org/10.1371/journal.pone.0178584
Liu W, Mu R, Nie FF et al (2009) MAC related mitochondrial pathway in oroxylin A induces apoptosis in human hepatocellular carcinoma HepG2 cells. Cancer Lett 284:198–207. https://doi.org/10.1016/j.canlet.2009.04.021
Liu PW, Chen MF, Tsai APY, Lee TJF (2012) STAT1 mediates oroxylin A inhibition of iNOS and pro-inflammatory cytokines expression in microglial BV-2 Cells. PLoS ONE 7:. https://doi.org/10.1371/journal.pone.0050363
Liu Y, Wang X, Li W et al (2020) Oroxylin A reverses hypoxia-induced cisplatin resistance through inhibiting HIF-1α mediated XPC transcription. Oncogene 39:6893–6905. https://doi.org/10.1038/s41388-020-01474-x
Lu Z, Lu N, Li C, Li F, Zhao K, Lin B, Guo Q (2012) Oroxylin A inhibits matrix metalloproteinase-2/9 expression and activation by up-regulating tissue inhibitor of metalloproteinase-2 and suppressing the ERK1/2 signaling pathway. Toxicol Lett 209:211–220. https://doi.org/10.1016/j.toxlet.2011.12.022
Lu L, Guo Q, Zhao L (2016) Overview of oroxylin A: a promising flavonoid compound. Phytother Res 30:1765–1774. https://doi.org/10.1002/PTR.5694
Luna J, Sotoca A, Fernández P et al (2021) Recent advances in early stage lung cancer. J Clin Transl Res 7:163. https://doi.org/10.18053/jctres.07.202102.010
Mercadante AA, Kasi A (2021) Genetics, cancer cell cycle phases. StatPearls Publishing
Mu R, Qi Q, Gu H, Wang J, Yang Y, Rong J, Liu W, Lu N, You Q, Guo Q (2009) Involvement of p53 in oroxylin A-induced apoptosis in cancer cells. Mol Carcinog 48:1159–1169. https://doi.org/10.1002/mc.20570
Ni T, He Z, Dai Y et al (2017) Oroxylin a suppresses the development and growth of colorectal cancer through reprogram of HIF1α-modulated fatty acid metabolism. Cell Death Dis 8:. https://doi.org/10.1038/cddis.2017.261
Nishida N, Yano H, Nishida T et al (2006) Angiogenesis in cancer. Vasc Health Risk Manage 2:213–219. https://doi.org/10.2147/VHRM.2006.2.3.213
Nyberg P, Xie L, Kalluri R (2005) Endogenous inhibitors of angiogenesis. Can Res 65:3967–3979. https://doi.org/10.1158/0008-5472.CAN-04-2427
Panieri E, Santoro MM (2016) ROS homeostasis and metabolism: a dangerous liason in cancer cells. Cell Death Dis 7:. https://doi.org/10.1038/CDDIS.2016.105
Petrovska BB (2012) Historical review of medicinal plants’ usage. Pharmacogn Rev 6:1–5. https://doi.org/10.4103/0973-7847.95849
Poonacha SK, Harishkumar M, Radha M et al (2021) Insight into oroxylina-7-o-β-d-glucuronide-enriched oroxylum indicum bark extract in oral cancer hsc-3 cell apoptotic mechanism: role of mitochondrial microenvironment. Molecules 26:. https://doi.org/10.3390/molecules26247430
Qiao C, Wei L, Dai Q et al (2015) UCP2-related mitochondrial pathway participates in oroxylin A-induced apoptosis in human colon cancer cells. J Cell Physiol 230:1054–1063. https://doi.org/10.1002/jcp.24833
Qiao C, Lu N, Zhou Y et al (2016) Oroxylin a modulates mitochondrial function and apoptosis in human colon cancer cells by inducing mitochondrial translocation of wild-type p53. Oncotarget 7:17009–17020. https://doi.org/10.18632/oncotarget.7927
Ren G, Chen H, Zhang M et al (2020a) Determination of oroxylin A, oroxylin A 7-O-glucuronide, and oroxylin A sodium sulfonate in beagle dogs by using UHPLC MS/MS application in a pharmacokinetic study. J Sep Sci 43:2290–2300. https://doi.org/10.1002/jssc.201901259
Ren G, Chen H, Zhang M et al (2020b) Pharmacokinetics, tissue distribution and excretion study of oroxylin A, oroxylin A 7-O-glucuronide and oroxylin A sodium sulfonate in rats after administration of oroxylin A. Fitoterapia 142:104480. https://doi.org/10.1016/j.fitote.2020.104480
Riabov V, Gudima A, Wang N et al (2014) Role of tumor associated macrophages in tumor angiogenesis and lymphangiogenesis. Front Physiol 5:. https://doi.org/10.3389/FPHYS.2014.00075
Sharma D, Goel N, Garg VK (2022) Predicting survivability in oral cancer patients. Algorithms for Intelligent Systems. Springer, Singapore, pp 153–162
Shen L, Zhang LL, Li H et al (2017) Oroxylin A inhibits the generation of Tregs in non-small cell lung cancer. Oncotarget 8:49395–49408. https://doi.org/10.18632/oncotarget.17218
Shen JJ, Zhu XF, Xu J et al (2020a) Oroxylin A exerts anticancer effects on human ovarian cancer cells via the PPARγ-dependent reversal of the progesterone receptor membrane component 1/2 expression profile. Oncol Rep 43:1309–1318. https://doi.org/10.3892/or.2020.7509
Shen M, Guo M, Wang Z et al (2020b) ROS-dependent inhibition of the PI3K/Akt/mTOR signaling is required for Oroxylin A to exert anti-inflammatory activity in liver fibrosis. Int Immunopharmacol 85:. https://doi.org/10.1016/j.intimp.2020.106637
Shimizu T, Shibuya N, Narukawa Y et al (2018) Synergistic effect of baicalein, wogonin and oroxylin A mixture: multistep inhibition of the NF-κB signalling pathway contributes to an anti-inflammatory effect of Scutellaria root flavonoids. J Nat Med 72:181–191. https://doi.org/10.1007/s11418-017-1129-y
Song X, Chen Y, Sun Y et al (2012) Oroxylin A, a classical natural product, shows a novel inhibitory effect on angiogenesis induced by lipopolysaccharide. Pharmacol Rep 64:1189–1199. https://doi.org/10.1016/S1734-1140(12)70915-5
Sonoda M, Nishiyama T, Matsukawa Y, Moriyasu M (2004) Cytotoxic activities of flavonoids from two Scutellaria plants in Chinese medicine. J Ethnopharmacol 91:65–68. https://doi.org/10.1016/j.jep.2003.11.014
Srivani G, Peela S, Alam A, Nagaraju GP (2021) Gemcitabine for pancreatic cancer. Cancer Plus S1:20–32. https://doi.org/10.18063/CP.V3I3.323
Sulaiman RS, Basavarajappa HD, Corson TW (2014) Natural product inhibitors of ocular angiogenesis. Exp Eye Res 129:161–171. https://doi.org/10.1016/j.exer.2014.10.002
Sun Y, Lu N, Ling Y, Gao Y, Chen Y, Wang L, Hu R, Qi Q, Liu W, Yang Y, You Q, Guo Q (2009) Oroxylin A suppresses invasion through down-regulating the expression of matrix metalloproteinase-2/9 in MDA-MB-435 human breast cancer cells. Eur J Pharmacol 603:22–28. https://doi.org/10.1016/j.ejphar.2008.12.008
Sun XH, Chang X, Wang Y et al (2019) Oroxylin A suppresses the cell proliferation, migration, and EMT via NF-B signaling pathway in human breast cancer cells. BioMed Res Int 2019:. https://doi.org/10.1155/2019/9241769
Tan C, Qian X, Ge Y et al (2017) Oroxylin a could be a promising radiosensitizer for esophageal squamous cell carcinoma by inducing G2/M Arrest and activating apoptosis. Pathol Oncol Res 23:323–328. https://doi.org/10.1007/s12253-016-0106-1
Tuli HS, Kashyap D, Sharma AK, Sandhu SS (2015a) Molecular aspects of melatonin (MLT)-mediated therapeutic effects. Life Sci 135:147–157. https://doi.org/10.1016/J.LFS.2015.06.004
Tuli HS, Kumar G, Sandhu SS et al (2015b) Apoptotic effect of cordycepin on A549 human lung cancer cell line. Turk J Biol 39:306–311. https://doi.org/10.3906/biy-1408-14
Tuli HS, Aggarwal V, Kaur J et al (2020) Baicalein: a metabolite with promising antineoplastic activity. Life Sci 259:118183. https://doi.org/10.1016/j.lfs.2020.118183
Tuli HS, Sak K, Iqubal A et al (2022) STAT signaling as a target for intervention: from cancer inflammation and angiogenesis to non-coding RNAs modulation. Mol Biol Rep. https://doi.org/10.1007/s11033-022-07399-w
Valladares BT, Crespo PC, Herranz UA, Caamaño AG (2021) Adjuvant treatment in lung cancer. J Clin Transl Res 7:175–184. https://doi.org/10.18053/jctres.07.202102.012
Varshney P, Saini N (2018) PI3K/AKT/mTOR activation and autophagy inhibition plays a key role in increased cholesterol during IL-17A mediated inflammatory response in psoriasis. Biochimica et Biophysica Acta - Mol Basis Dis 1864:1795–1803. https://doi.org/10.1016/j.bbadis.2018.02.003
Wang X, Wang Y, Geng Y et al (2004) Isolation and purification of honokiol and magnolol from cortex Magnoliae officinalis by high-speed counter-current chromatography. J Chromatogr A 1036:171–175. https://doi.org/10.1016/j.chroma.2004.02.073
Wang Z, Dabrosin C, Yin X et al (2015) Broad targeting of angiogenesis for cancer prevention and therapy. Semin Cancer Biol 35(Suppl):S224–S243. https://doi.org/10.1016/J.SEMCANCER.2015.01.001
Wang Y-l, Gao J-m, Xing LZ (2016) Therapeutic potential of oroxylin A in rheumatoid arthritis. Int Immunopharmacol 40:294–299. https://doi.org/10.1016/j.intimp.2016.09.006
Wei L, Dai Q, Zhou Y et al (2013) Oroxylin A sensitizes non-small cell lung cancer cells to anoikis via glucose-deprivation-like mechanisms: C-Src and hexokinase II. Biochim Biophys Acta Gen Subj 1830:3835–3845. https://doi.org/10.1016/j.bbagen.2013.03.009
Wei L, Zhou Y, Qiao C et al (2015) Oroxylin A inhibits glycolysis-dependent proliferation of human breast cancer via promoting SIRT3-mediated SOD2 transcription and HIF1α destabilization. Cell Death Dis 6:e1714–e1714. https://doi.org/10.1038/cddis.2015.86
Wei L, Yao Y, Zhao K et al (2016) Oroxylin A inhibits invasion and migration through suppressing ERK/GSK-3β signaling in snail-expressing non-small-cell lung cancer cells. Mol Carcinog 55:2121–2134. https://doi.org/10.1002/mc.22456
Wei L, Dai Y, Zhou Y et al (2017) Oroxylin a activates pkm1/hnf4 alpha to induce hepatoma differentiation and block cancer progression. Cell Death Dis 8:e2944–e2944. https://doi.org/10.1038/cddis.2017.335
Wei M, Ma R, Huang S et al (2019) Oroxylin A increases the sensitivity of temozolomide on glioma cells by hypoxia-inducible factor 1α/hedgehog pathway under hypoxia. J Cell Physiol 234:17392–17404. https://doi.org/10.1002/jcp.28361
Wong RSY (2011) Apoptosis in cancer: from pathogenesis to treatment. J Exp Clin Cancer Res: CR 30:. https://doi.org/10.1186/1756-9966-30-87
Xie R (2021) Combining pd-1/pd-l1 inhibitor and parp inhibitor: a new perspec-tive on the treatment of triple negative breast cancer. Trends Immunother 5:24–29. https://doi.org/10.24294/ti.v5.i2.1.1372
Xing S, Wang M, Peng Y et al (2014) Simulated gastrointestinal tract metabolism and pharmacological activities of water extract of Scutellaria baicalensis roots. J Ethnopharmacol 152:183–189. https://doi.org/10.1016/j.jep.2013.12.056
Xu ZF, Sun XK, Chen G et al (2018) Oroxyloside inhibits human glioma progression by suppressing proliferation, metastasis and inducing apoptosis related pathways. Biomed Pharmacother 97:1564–1574. https://doi.org/10.1016/j.biopha.2017.09.100
Xuan L, Zhang J, Ji J et al (2020) Oroxylin a exerts its antitumor effects in human gallbladder cancer via inhibition of the PTEN/PI3K/AKT signaling pathway. Biol Pharm Bull 43:1511–1518. https://doi.org/10.1248/bpb.b20-00262
Yadav P, Jaswal V, Sharma A et al (2018) Celastrol as a pentacyclic triterpenoid with chemopreventive properties. Pharmaceutical Patent Analyst 7:155–167. https://doi.org/10.4155/ppa-2017-0035
Yang H, Li J, Zheng Y et al (2016) Drug activity screening based on microsomes-hydrogel system in predicting metabolism induced antitumor effect of oroxylin A. Sci Rep 6:. https://doi.org/10.1038/srep21604
Yang Y, Hu Y, Gu H-Y et al (2010) Oroxylin A induces G2/M phase cell-cycle arrest via inhibiting Cdk7-mediated expression of Cdc2/p34 in human gastric carcinoma BGC-823 cells. J Pharm Pharmacol 60:1459–1463. https://doi.org/10.1211/jpp.60.11.0006
Yang Y, Hu Y, Gu H-Y et al (2008) Oroxylin A induces G2/M phase cell-cycle arrest via inhibiting Cdk7-mediated expression of Cdc2/p34 in human gastric carcinoma BGC-823 cells. J Pharm Pharmacol 60:1459–1463. https://doi.org/10.1211/jpp/60.11.0006
Yang X, Zhang F, Wang Y et al (2013) Oroxylin A inhibits colitis-associated carcinogenesis through modulating the IL-6/STAT3 signaling pathway. Inflamm Bowel Dis 19:1990–2000. https://doi.org/10.1097/MIB.0b013e318293c5e0
Yao J, Hu R, Sun J et al (2014) Oroxylin a prevents inflammation-related tumor through down-regulation of inflammatory gene expression by inhibiting NF-κB signaling. Mol Carcinog 53:145–158. https://doi.org/10.1002/mc.21958
Yao J, yue, Xu S, Sun Y ning, et al (2022) Novel CDK9 inhibitor oroxylin A promotes wild-type P53 stability and prevents hepatocellular carcinoma progression by disrupting both MDM2 and SIRT1 signaling. Acta Pharmacol Sin 43:1033–1045. https://doi.org/10.1038/s41401-021-00708-2
Yang Y, Ren L, Yang H, Ge B, Li W, Wang Y, Wang H, Du G, Tang B, Wang J (2021) Research progress on anti-angiogenesis drugs in hepatocellular carcinoma. Cancer Plus 3:33. https://doi.org/10.18063/CP.V3I2.319
Yuan SY, Rigor RR (2011) Regulation of endothelial barrier function. Colloquium Series on Integrated Systems Physiology: From Molecule to Function 3:1–146. https://doi.org/10.4199/c00025ed1v01y201101isp013
Zhang Q, Cong D, An D et al (2018) Determination of oroxylin A and oroxylin A 7-O-D-glucuronide in HepG2 cell lysate and subcellular fractions with SPE-UPLC–MS/MS: cellular pharmacokinetic study to indicate anti-cancer mechanisms. J Pharm Biomed Anal 154:364–372. https://doi.org/10.1016/j.jpba.2018.03.019
Zhang WB, Zheng YF, Wu YG (2021a) Protective effects of oroxylin A against doxorubicin-induced cardiotoxicity via the activation of Sirt1 in mice. Oxidative Med Cell Longev 2021:. https://doi.org/10.1155/2021/6610543
Zhang Y, Weng Q, Chen J et al (2021b) Oroxylin A attenuates IL‑1β‑induced inflammatory reaction via inhibiting the activation of the ERK and PI3K/AKT signaling pathways in osteoarthritis chondrocytes. Exp Ther Med 21:. https://doi.org/10.3892/etm.2021.9819
Zhang Z, Shi J, Nice EC et al (2021c) The multifaceted role of flavonoids in cancer therapy: leveraging autophagy with a double-edged sword. Antioxidants 10:1138. https://doi.org/10.3390/antiox10071138
Zhao L, Chen Z, Wang J et al (2010) Synergistic effect of 5-fluorouracil and the flavanoid oroxylin A on HepG2 human hepatocellular carcinoma and on H22 transplanted mice. Cancer Chemother Pharmacol 65:481–489. https://doi.org/10.1007/s00280-009-1053-2
Zhao K, Zhou Y, Qiao C et al (2015) Oroxylin A promotes PTEN-mediated negative regulation of MDM2 transcription via SIRT3-mediated deacetylation to stabilize p53 and inhibit glycolysis in wt-p53 cancer cells. J Hematol Oncol 8:. https://doi.org/10.1186/s13045-015-0137-1
Zhao K, Li X, Lin B et al (2018) Oroxyloside inhibits angiogenesis through suppressing internalization of VEGFR2/Flk-1 in endothelial cells. J Cell Physiol 233:3454–3464. https://doi.org/10.1002/jcp.26198
Zhou Q, Zheng Z, Xia B et al (2010) Use of isoform-specific UGT metabolism to determine and describe rates and profiles of glucuronidation of wogonin and oroxylin a by human liver and intestinal microsomes. Pharm Res 27:1568–1583. https://doi.org/10.1007/s11095-010-0148-0
Zhou W, Liu X, Zhang X et al (2017) Oroxylin A inhibits colitis by inactivating NLRP3 inflammasome. Oncotarget 8:58903–58917. https://doi.org/10.18632/oncotarget.19440
Zhu X, Chen Y, Zhu W et al (2019) Oroxylin A inhibits Kaposi’s sarcoma-associated herpes virus (KSHV) vIL-6–mediated lymphatic reprogramming of vascular endothelial cells through modulating PPARγ/Prox1 axis. J Med Virol 91:463–472. https://doi.org/10.1002/jmv.25337
Zhu Y, Guo Y, Liu M et al (2020) An oroxylin a-loaded aggregation-induced emission active polymeric system greatly increased the antitumor efficacy against squamous cell carcinoma. J Mater Chem B 8:2040–2047. https://doi.org/10.1039/c9tb01818b
Acknowledgements
ICMR-DHR Young scientist fellowship to TS (F.NO: R. 12014/29/2022/HR).
Author information
Authors and Affiliations
Contributions
HST, VKG, and AK: collection of data and analysis of data; DA and UA: designed the “Introduction” and tables section: NCP: contributed to synergistic section; AKS, RKM, KD, MK, and TS: contributed to chemistry, metabolism, and nano delivery section; JK and KS: contributed in anti-inflammation and conclusion section.
Corresponding author
Ethics declarations
Ethical approval
Not applicable.
Consent to participate
Not applicable.
Consent for publication
All authors have their consent to publish.
Competing interests
The authors declare no competing interests.
Additional information
Publisher’s note
Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.
Rights and permissions
Springer Nature or its licensor (e.g. a society or other partner) holds exclusive rights to this article under a publishing agreement with the author(s) or other rightsholder(s); author self-archiving of the accepted manuscript version of this article is solely governed by the terms of such publishing agreement and applicable law.
About this article
Cite this article
Tuli, H.S., Garg, V.K., Kumar, A. et al. Anticancer potential of oroxylin A: from mechanistic insight to synergistic perspectives. Naunyn-Schmiedeberg's Arch Pharmacol 396, 191–212 (2023). https://doi.org/10.1007/s00210-022-02298-0
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1007/s00210-022-02298-0